About this trial
Aortic stenosis is highly prevalent in advancing age. The prognosis of this disease has dramatically changed with the surgical replacement of the aortic valve and the trans catheter aortic valve re-placement (TAVI). The TAVI procedure is also successful in octogenarians and frail patients. However, the evaluation before the TAVI procedure requires a high dosage of iodinated contrast agent with, consequently, an increased risk for thyroid dysfunction. The primary endpoint of this study is to assess, prospectively, the incidence and the predictive factors (underlying thyroid disease, medication, food preservative, topical antiseptics) of hypothyroidism after a TAVI procedure. The secondary endpoint is the influence of the occurrence of hypothyroidism after the TAVI procedure on the geriatric assessment.
Eligibility criteria
Qualifiers
Provision of signed and dated, written Informed Consent prior to any study specific proce-dures
Patient: males and females must be ≥ 70 years old
Patients who will undergo a TAVI procedure
Disqualifiers
- No obtained signed, dated and written Informed Consent.
Known thyroid dysfunction (for example: Basedow, Hashimoto,...)
Patients receiving any of the following: Lithium, Strumazol or a recent treatment of radio-Iode
Trial design
Treatments tested in this trial
- Assesment of thyroïd function